Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

Part of paid clinical trials in Kingsport, Tennessee.

Sponsor
Ballad Health
Study ID
NCT06849518
Status
Recruiting
Apply to this trial

Conditions

  • Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Circulogene liquid biopsy testing — DIAGNOSTIC_TEST
    A Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.

Study Details

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Key Dates

Start date
Feb 11, 2025
Status verified
Feb 2025
Primary completion
Mar 1, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: plasma NGS ctDNA and plasma cfRNA PD-L1 expression

Primary Outcome Measure

Correlation of plasma cfRNA PD-L1 by qPCR expression* with ICI treatment and response. [ Time Frame: up to 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ballad Health Cancer CareKingsportTennessee37660
Charles Mays, PhD, CCRP, CCRC
[email protected]
423-431-5654

Find similar trials in Kingsport, TN

By research site
Ballad Health Cancer Care· Kingsport, TN

Related Studies